文献速递头颈CT

基于增强CT影像组学模型识别局部晚期鼻咽癌降强度放化疗候选患者

A contrast-enhanced CT radiomics-based model to identify candidates for deintensified chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma patients.
PubMed 文献 · Eur Radiol · 2023-08-18

本研究开发基于增强CT的影像组学模型,用于识别可从降强度放化疗获益的局部晚期鼻咽癌患者。影像组学评分联合N分期的R+N模型预测能力优于T+N模型(C-index 0.77 vs 0.68,AUC 0.80 vs 0.70),低风险组5年无进展生存率和总生存率均为90.7%。

要点

  • 影像组学评分联合N分期的R+N模型C-index为0.77,优于T+N模型的0.68。
  • R+N模型识别的低风险组接受降强度治疗后3年内无进展,5年PFS和OS均为90.7%。
  • 基于原发鼻咽肿瘤的影像组学评分预测能力优于传统T分期(C-index 0.67 vs 0.61)。

核心结论

  • 基于影像组学评分联合N分期的模型可识别特定局部晚期鼻咽癌候选患者,对此类患者实施降强度治疗不损害疗效。

研究设计与样本

  • 研究纳入接受低剂量同步顺铂化疗(累积150 mg/m2)的局部晚期鼻咽癌患者,随机分为训练组66例和验证组33例;从每例治疗前增强CT扫描提取基于原发鼻咽肿瘤的107个影像组学特征,通过Cox回归分析建立影像组学模型及评分。

关键影像表现/征象

  • 筛选出3个显著独立影像组学特征:flatness、mean和灰度依赖矩阵中的灰度非均匀性(GLDM-GLN)。

诊断标准与关键数值

  • 影像组学评分预测能力优于T分期:C-index 0.67 vs 0.61,AUC 0.75 vs 0.60。
  • R+N模型预测性能和风险分层优于T+N模型:C-index 0.77 vs 0.68,AUC 0.80 vs 0.70。
  • R+N模型识别的低风险组接受降强度放化疗后3年内无患者出现进展,5年无进展生存率和总生存率均为90.7%(HR=4.132,p=0.018)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To develop a contrast-enhanced CT (CECT) radiomics-based model to identify locoregionally advanced nasopharyngeal carcinoma (LA-NPC) patients who would benefit from deintensified chemoradiotherapy.

METHODS: LA-NPC patients who received low-dose concurrent cisplatin therapy (cumulative: 150 mg/m2), were randomly divided into training and validation groups. 107 radiomics features based on the primary nasopharyngeal tumor were extracted from each pre-treatment CECT scan. Through Cox regression analysis, a radiomics model and patients' corresponding radiomics scores were created with predictive independent radiomics features. T stage (T) and radiomics score (R) were compared as predictive factors. Combining the N stage (N), a clinical model (T + N), and a substitution model (R + N) were constructed.

RESULTS: Training and validation groups consisted of 66 and 33 patients, respectively. Three significant independent radiomics features (flatness, mean, and gray level non-uniformity in gray level dependence matrix (GLDM-GLN)) were found. The radiomics score showed better predictive ability than the T stage (concordance index (C-index): 0.67 vs. 0.61, AUC: 0.75 vs. 0.60). The R + N model had better predictive performance and more effective risk stratification than the T + N model (C-index: 0.77 vs. 0.68, AUC: 0.80 vs. 0.70). The R + N model identified a low-risk group as deintensified chemoradiotherapy candidates in which no patient developed progression within 3 years, with 5-year progression-free survival (PFS) and overall survival (OS) both 90.7% (hazard ratio (HR) = 4.132, p = 0.018).

CONCLUSION: Our radiomics-based model combining radiomics score and N stage can identify specific LA-NPC candidates for whom de-escalation therapy can be performed without compromising therapeutic efficacy.

CLINICAL RELEVANCE STATEMENT: Our study shows that the radiomics-based model (R + N) can accurately stratify patients into different risk groups, with satisfactory prognosis in the low-risk group when treated with low-dose concurrent chemotherapy, providing new options for individualized de-escalation strategies.

KEY POINTS: • A radiomics score, consisting of 3 predictive radiomics features (flatness, mean, and GLDM-GLN) integrated with the N stage, can identify specific LA-NPC populations for deintensified treatment. • In the selection of LA-NPC candidates for de-intensified treatment, radiomics score extracted from primary nasopharyngeal tumors based on CECT can be superior to traditional T stage classification as a predictor.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lin Y, Yang Z, Chen J, et al. A contrast-enhanced CT radiomics-based model to identify candidates for deintensified chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma patients. Eur Radiol. 2023. PMID: 37594526. doi:10.1007/s00330-023-09987-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。